LifeStance Health Group, Inc.

NasdaqGS LFST

LifeStance Health Group, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 2.46

LifeStance Health Group, Inc. Price to Sales Ratio (P/S) is 2.46 on January 14, 2025, a -0.85% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

LifeStance Health Group, Inc. 52-week high Price to Sales Ratio (P/S) is 3.16 on February 28, 2024, which is 28.24% above the current Price to Sales Ratio (P/S).
LifeStance Health Group, Inc. 52-week low Price to Sales Ratio (P/S) is 1.64 on July 01, 2024, which is -33.21% below the current Price to Sales Ratio (P/S).
LifeStance Health Group, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 2.19.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: LFST

LifeStance Health Group, Inc.

CEO	Mr. Kenneth Alan Burdick
IPO Date	June 10, 2021
Location	United States
Headquarters	4800 N. Scottsdale Road
Employees	7,269
Sector	Health Care
Industries Mental Health Telehealth

Description

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates outpatient mental health platform as well as offers patients care virtually through its online delivery platform or in-person at its centers in 32 states. It serves children, adolescents, adults, and geriatrics. LifeStance Health Group, Inc. was founded in 2017 and is based in Scottsdale, Arizona.

Key trends

Past 5 years